Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Affiliation auteurs!!!! Error affiliation !!!!
TitreClinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Type de publicationJournal Article
Year of Publication2019
AuteursDaver NG, Montesinos P, DeAngelo DJ, Wang ES, Papadantonakis N, Deconinck E, Erba HP, Pemmaraju N, Lane AA, Rizzieri DA, Sweet KL, Martinelli G, Tarella C, Todisco E, Konopleva MY, Sloss CM, Culm-Merdek K, Zweidler-McKay PA, Kantarjian HM
JournalBLOOD
Volume134
Date PublishedNOV 13
Type of ArticleMeeting Abstract
ISSN0006-4971
DOI10.1182/blood-2019-128648